The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RVPH | -58.5% | -95.38% | -45.9% | -95% |
| S&P | +13.19% | +87.83% | +13.42% | +143% |
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $35.51M | -25.5% |
| Market Cap / Employee | $2.54M | 0.0% |
| Employees | 14 | -6.7% |
| Net Income | -$4.01M | 52.1% |
| EBITDA | -$4.03M | 52.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $13.18M | 137.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -207.23% | 305.7% |
| Return On Invested Capital | -957.17% | -736.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$5.59M | -31.8% |
| Operating Free Cash Flow | -$5.59M | -31.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -6.06 | 54.69 | -3.99 | -54.61 | 668.37% |
| Price to Tangible Book Value | -6.06 | 54.67 | -3.99 | -54.59 | 668.16% |
| Enterprise Value to EBITDA | -9.97 | -6.32 | -1.44 | -3.38 | -33.85% |
| Return on Equity | -435.4% | -1806.3% | -916.2% | - | |
| Total Debt | $0.46M | $0.22M | $0.11M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
